Skip to main content Skip to main navigation menu Skip to site footer

Autologous Serum Eye Drops (ASEDs) as dry eye disease treatment option



Abstract

Background: Nowadays, there are a lot of treatment options available for dry eye syndrome (DES) or disease (DED). Autologous Serum Eye Drops (ASEDs) is one of the options that offer a potential advantage over conventional therapy. Biochemical elements in ASEDs resemble real tears and act as a lacrimal substitute to provide lubrication. As a severe dry eye treatment, using ASEDs has grown in favor.

Aim: This review aims to deliver knowledge from the current literature on applying ASEDs for dry eye disease in the medical worker.

Method: The method used was a literature review. A comprehensive search was performed on Pubmed and Google Scholar databases in December 2022 using each of the following keywords “ASEDs”, “serum”, “eyedrop”, “DED” and “DES”.

Conclusion: Dry eye disease is incurable and symptom management is the focus of therapy.     Studies have shown that ASEDs reduced dry eye symptoms in over 60% of patients by inhibiting the release of inflammatory cytokines and increasing the number of goblet cells and mucin expression in the conjunctiva. The serum eye drop is typically well tolerated and can be one of the best treatment options for severe DED due to its close resemblance to tears, preservatives free and minimum side effects. 

Keywords: Autologous serum Dry eye Severe Tears Treatment

References

  1. Higuchi A. Autologous Serum and Serum Components. Invest Ophthalmol Vis Sci. 2018;59(14):DES121–9. Available from: https://doi.org/10.1167/iovs.17-23760
  2. Wang L, Cao K, Wei Z, Baudouin C, Labbé A, Liang Q. Autologous Serum Eye Drops versus Artificial Tear Drops for Dry Eye Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Ophthalmic Res. 2020;63(5):443–51. Available from: https://www.karger.com/DOI/10.1159/000505630
  3. Sriwidodo S, Syah ISK, Maksum IP, Subroto T, Zasvia U, Umar AK. Stabilization of eye drops containing autologous serum and recombinant human epidermal growth factor for dry eye syndrome. J Adv Pharm Technol Res. 2020;11(4):184–8.
  4. Pan Q, Angelina A, Marrone M, Stark WJ, Akpek EK. Autologous serum eye drops for dry eye. Cochrane Database of Systematic Reviews. 2017;(2). Available from: https://doi.org//10.1002/14651858.CD009327.pub3
  5. Zhang X, Wang L, Zheng Y, Deng L, Huang X. Prevalence of dry eye disease in the elderly: A protocol of systematic review and meta-analysis. Medicine. 2020;99(37). Available from: https://journals.lww.com/md-journal/Fulltext/2020/09110/Prevalence_of_dry_eye_disease_in_the_elderly__A.93.aspx
  6. Persatuan Dokter Mata Indonesia. PEDOMAN NASIONAL PELAYANAN KEDOKTERAN DRY EYE [Internet]. 2022. Available from: https://perdami.or.id/wp-content/uploads/2022/03/PNPK-Dry-Eye-Final.pdf
  7. Akpek EK, Amescua G, Farid M, Garcia-Ferrer FJ, Lin A, Rhee MK, et al. Dry Eye Syndrome Preferred Practice Pattern®. Ophthalmology. 2019;126(1):P286–334.
  8. Clayton JA. Dry Eye. New England Journal of Medicine. 2018;378(23):2212–23. Available from: https://doi.org/10.1056/NEJMra1407936
  9. Shtein RM, Shen JF, Kuo AN, Hammersmith KM, Li JY, Weikert MP. Autologous Serum-Based Eye Drops for Treatment of Ocular Surface Disease: A Report by the American Academy of Ophthalmology. Ophthalmology. 2020;127(1):128–33. Available from: https://doi.org/10.1016/j.ophtha.2019.08.018
  10. Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo C-K, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15(3):276–83. Available from: https://www.sciencedirect.com/science/article/pii/S1542012417301192
  11. de Pascale MR, Lanza M, Sommese L, Napoli C. Human Serum Eye Drops in Eye Alterations: An Insight and a Critical Analysis. Mantelli F, editor. J Ophthalmol. 2015;2015:396410. Available from: https://doi.org/10.1155/2015/396410
  12. Golden MI, Meyer JJ, Patel BC. Dry Eye Syndrome [Internet]. StatPearls. 2022. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28736335
  13. Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438–510. Available from: https://www.sciencedirect.com/science/article/pii/S1542012417301349
  14. Shigeyasu C, Yamada M, Yokoi N, Kawashima M, Suwaki K, Uchino M, et al. Characteristics and Utility of Fluorescein Breakup Patterns among Dry Eyes in Clinic-Based Settings. Diagnostics. 2020;10(9). Available from: https://www.mdpi.com/2075-4418/10/9/711
  15. Jones L, Downie LE, Korb D, Benitez-del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017;15(3):575–628. Available from: https://www.sciencedirect.com/science/article/pii/S1542012417301143
  16. The Royal College of Ophtamologist. Serum Eye Drops for the Treatment of Severe Ocular Surface Disease [Internet]. 2017. Available from: https://www.rcophth.ac.uk/wp-content/uploads/2020/07/Serum-Eye-Drops-Guideline.pdf
  17. Marshall LL, Roach JM. Treatment of Dry Eye Disease. The Consultant Pharmacist. 2016;31(2).
  18. Prasetyo K, Heryati S. Therapeutic Effect of Autologous Serum Eye Drops on Aqueous Tear-Deficiency and Evaporative Tear-Deficiency Cases. Ophthalmologica Indonesiana. 2016;42(1). Available from: https://perdami.or.id/ophthalmologica/journal/article/view/57
  19. Agung SS, Maksum IP, Subroto T. Serum otologus dan human epidermal growth factor (hEGF) mempercepat proliferasi dan migrasi keratinosit pada proses re-epitelisasi. Majalah Kedokteran Bandung. 2016;48(4):205–10.
  20. Mahelkova G, Jirsova K, Seidler stangova P, Palos M, Vesela V, Fales I, et al. Using corneal confocal microscopy to track changes in the corneal layers of dry eye patients after autologous serum treatment. Clin Exp Optom. 2017;100(3):243–9. Available from: https://doi.org/10.1111/cxo.12455
  21. Celebi ARC, Ulusoy C, Mirza GE. The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2014;252(4):619–26. Available from: https://doi.org/10.1007/s00417-014-2599-1
  22. Thanathanee O, Phanphruk W, Anutarapongpan O, Romphruk A, Suwan-apichon O. Contamination Risk of 100% Autologous Serum Eye Drops in Management of Ocular Surface Diseases. Cornea. 2013;32(8). Available from: https://journals.lww.com/corneajrnl/Fulltext/2013/08000/Contamination_Risk_of_100__Autologous_Serum_Eye.11.aspx
  23. van der Meer PF, Verbakel SK, Honohan Á, Lorinser J, Thurlings RM, Jacobs JFM, et al. Allogeneic and autologous serum eye drops: a pilot double-blind randomized crossover trial. Acta Ophthalmol. 2021;99(8):837–42. Available from: https://doi.org/10.1111/aos.14788
  24. Partal A, Scott E. Low-cost protocol for the production of autologous serum eye drops by blood collection and processing centres for the treatment of ocular surface diseases. Transfusion Medicine. 2011;21(4):271–7. Available from: https://doi.org/10.1111/j.1365-3148.2011.01072.x

How to Cite

Anak Agung Ayu Putri Oktiadewi, & I Putu Rustama Putra. (2023). Autologous Serum Eye Drops (ASEDs) as dry eye disease treatment option. Intisari Sains Medis, 14(1). https://doi.org/10.15562/ism.v14i1.1626
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
0

Total
0

Share

Search Panel

Anak Agung Ayu Putri Oktiadewi
Google Scholar
Pubmed
ISM Journal

I Putu Rustama Putra
Google Scholar
Pubmed
ISM Journal